A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Clinical trial NCT02108964 · COMPLETED

Trial details

NCT number: NCT02108964
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Non-small Cell Lung Cancer

Start date: 2014-06-06
Primary completion: 2018-03-22
Enrollment: 225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.